Nepal Heart Foundation, Pulchowk, Lalitpur, Nepal.
HAMS Hospital, Mandikhatar Road, Kathmandu, Nepal.
JNMA J Nepal Med Assoc. 2022 Sep 1;60(253):832-835. doi: 10.31729/jnma.7861.
A secondary level of prophylaxis has proven to be the most successful in Nepal, a country with an endemic rate of rheumatic heart disease, in combating the severe issues associated with rheumatic heart disease. The use of benzathine penicillin G in secondary prophylaxis of rheumatic heart disease, recommended by several guidelines, has been increasingly abandoned in Nepal due to a lack of national guidelines and the termination of the prior programs. The use of oral penicillin and alternative oral antibiotics, which are less effective in preventing the recurrence of acute rheumatic fever, is on the rise. Nepal urgently needs to develop new national guidelines and ensure their effective implementation in order to slow the increase in the number of rheumatic heart disease patients. In this article, we explore the limitations, challenges, and advantages of using the consensus-supported intramuscular benzathine penicillin G as the first-line drug for the secondary prevention of rheumatic heart disease.
在尼泊尔,一种针对风湿性心脏病的二级预防措施被证明是最成功的,该国风湿性心脏病的流行率很高。使用苄星青霉素 G 进行风湿性心脏病的二级预防,这是几个指南推荐的方法,由于缺乏国家指南和先前项目的终止,在尼泊尔已经越来越被放弃。使用口服青霉素和替代口服抗生素的情况正在增加,这些抗生素在预防急性风湿热复发方面效果较差。尼泊尔迫切需要制定新的国家指南,并确保其有效实施,以减缓风湿性心脏病患者数量的增加。在本文中,我们探讨了使用共识支持的肌肉内苄星青霉素 G 作为风湿性心脏病二级预防的一线药物的局限性、挑战和优势。